University of Chicago
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
Inclusion Criteria: * Patients must have pathologically confirmed locally advanced, non-metastatic, human papillomavirus (HPV) negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses. * Stage III or IV disease based on American Joint Committee on Cancer (AJCC) staging 8th edition. * If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry. * Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior t…
Given as part of induction chemotherapy.
Given as part of induction chemotherapy.
Given as part of induction chemotherapy.
Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Arctuva estimate
Verify or correct the compensation shown for this listing.